According to a report by Tracxn, total funding for India’s pharma and healthcare sectors in August 2025 stood at $47 million across seven rounds. This marked a decrease of 82.83 per cent from July 2025’s $274 million and an 82.26 per cent fall compared to August 2024.
Stage-wise funding trends showed that private equity funding accounted for 76.5 per cent of total investments. Early-stage funding contributed 21.3 per cent, while seed-stage funding represented 2.2 per cent.
The most notable funding round in August 2025 was secured by Aragen, which raised $36.0 million. Other rounds included Eyestem at $10.0 million, Aethermt at $0.5 million, QRL Bioscience at $0.3 million, and Cureous at $0.2 million.
Anthill Ventures participated in two funding rounds for Cureous and Aethermt. Gujarat Venture Finance supported one funding round for QRL Bioscience, while Inflection Point Ventures was involved in one round for Cureous.
Key takeaways from the Tracxn report include a slowdown in funding, with August 2025 registering a decline of over 82 per cent from both the previous month and the same month last year. Private equity funding dominated investments, capturing more than 76 per cent of the capital. The report also noted smaller deal sizes, with the largest deal being Aragen’s $36.0 million round, which was considerably smaller compared to July 2025.